{"status":"success","data":{"title":"Supratherapeutic INR","slug":"supratherapeutic-INR","tags":["coumadin","vitamin K","PCC","FFP","aspirin","clopidogrel,"],"collection":["hematology/oncology"],"content":"\n# Overanticoagulation and Supratherapeutic INR\n\n**ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)**\n\n| **INR**     | **Therapeutic intervention**  |\n|-------------|-------------------------------|\n| ≤ 10        | *If no bleeding:* Hold <span class=\"drug\">coumadin</span>. Restart when INR is therapeutic  |\n| &gt; 10     | *If no bleeding*: Hold <span class=\"drug\">coumadin</span>. Give oral <span class=\"drug\">vitamin K</span> (2.5 mg) |\n| Major bleed | Hold <span class=\"drug\">coumadin</span>. Give <span class=\"drug\">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class=\"drug\">PCC</span> (<span class=\"drug\">FFP</span> not of added benefit with <span class=\"drug\">PCC</span>) |\n\n**Higher bleeding risk associated with coumadin**\n\n-   *NSAIDS:* non-selective and COX-2 selective\n-   *Antiplatelet agents*: <span class=\"drug\">aspirin</span>, <span class=\"drug\">clopidogrel</span>\n-   ***Clotrimoxazole***\n-   *Antibiotics* (especially fluoroquinolones)\n\n**Pearl**\n\n-   Risk of intracranial hemorrhage doubles for every 1-point increase in INR\n\n## Causes for supratherapeutic INR &gt; 6\n\n[Hylek et al. JAMA 1998 study](https://www.ncbi.nlm.nih.gov/pubmed/9496982)\n\n-   Retrospective case-control study of patients with INR &gt; 6\n-   Enrolled 93 cases, 196 controls\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><strong>Risk factor/explanation</strong></th>\n<th><strong>OR</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td>Advanced malignancy</td>\n<td>16.4</td>\n</tr>\n<tr class=\"even\">\n<td><strong></strong>\n<p><span class=\"drug\">Acetaminophen</span> intake  4.5-9.1 g/wk<br />\n  &gt; 9.1 g/wk</p></td>\n<td><br />\n6.8<br />\n10</td>\n</tr>\n<tr class=\"odd\">\n<td>New medication</td>\n<td>8.5</td>\n</tr>\n<tr class=\"even\">\n<td>Excess <span class=\"drug\">coumadin</span> intake</td>\n<td>8.1</td>\n</tr>\n<tr class=\"odd\">\n<td>Decreased oral intake</td>\n<td>3.6</td>\n</tr>\n<tr class=\"even\">\n<td>Acute diarrheal illness</td>\n<td>3.5</td>\n</tr>\n<tr class=\"odd\">\n<td>Vitamin K intake</td>\n<td>0.7</td>\n</tr>\n<tr class=\"even\">\n<td>Alcohol use<br />\n(1 drink QOD-2 drinks daily)</td>\n<td>0.2</td>\n</tr>\n</tbody>\n</table>\n\n## References\n\n-   [Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62](https://www.ncbi.nlm.nih.gov/pubmed/9496982)\n-   [Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295.](https://www.ncbi.nlm.nih.gov/pubmed/22315259)\n"}}